By Sachin Ravikumar
BENGALURU, Aug 11 (Reuters) - India's supply of antiviral
drug remdesivir and generic equivalents is stabilising after
shortages of the vital COVID-19 medicine at hospitals, according
to a top executive at one of the country's big drugmakers, Cipla
Ltd CIPL.NS .
Remdesivir, made by U.S.-based Gilead Sciences Inc GILD.O ,
has been in high demand globally, and a handful of companies
including Cipla are authorised to make and sell generic versions
in 127 developing nations.
Cipla's launch of remdesivir in late June, along with
subsequent launches by others, has helped ease supply
bottlenecks in India, Cipla's Global Chief Financial Officer,
Kedar Upadhye, told Reuters.
"Of late, some of the complaints for supplies, and the
number of panicky calls that I used to get, have come down
dramatically," Upadhye said. "Looks like things have settled."
COVID-19 cases in India, the world's third-worst hit
country, have surged in the past month, with new infections
topping 50,000 daily.
Yet while hospitals previously reported they were struggling
to get their hands on the drug, leading to black market sales,
Upadhye said the indications from his supply chain were that
pressure had eased. urn:newsml:reuters.com:*:nL3N2ER25C
That suggested severe cases had not surged as much as the
overall numbers, he said.
Government data at the end of July showed about 0.3% of the
country's active coronavirus patients were on ventilators, while
1.6% on intensive care unit support and 2.3% on oxygen support.
Severe cases likely amounted to under 3% of all infections,
said Giridhara Babu, an epidemiologist at the Public Health
Foundation of India.
India, one of the world's biggest producer of generic drugs,
recommends remdesivir for moderate to severe COVID-19. Doctors
also use other drugs, including favirpiravir, another antiviral
approved for the disease.
Cipla, which is also free to export the drug, supplies it in
South Africa and plans to expand access to "several sub-Saharan
African countries", it has said.
India had previously blocked exports of another drug,
hydroxychloroquine, used by some doctors in treating the
disease. The ban has since been lifted.
Cipla declined to comment on the number of vials of
remdesivir it had shipped so far, but said it had started making
the drug at a plant in Goa in western India to ramp up
production.
(Reporting by Sachin Ravikumar, Anuron Kumar Mitra and Ankur
Banerjee in Bengaluru; editing by Patrick Graham and Saumyadeb
Chakrabarty)
((saisachin.r@tr.com; +91 80 6182 2754; Twitter: @sachinr27;))